Drug Trial Radar · NCT06958211
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
573
Actual
Start
Jun 12, 2025
Primary completion
Oct 1, 2026
Study completion Jul 11, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- May 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Conditions
- Hidradenitis Suppurativa
Interventions
Ruxolitinib CreamDrug
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Vehicle CreamDrug
Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baselineTime frame: Week 16
Locations
107 sites in 9 countries. Site status is shown where the registry gives one.
Investigative Site US257
Birmingham, Alabama
Investigative Site US218
Birmingham, Alabama
Investigative Site US239
Montgomery, Alabama
Investigative Site US215
Phoenix, Arizona
Investigative Site US261
Phoenix, Arizona
Investigative Site US240
Tucson, Arizona
Investigative Site US262
Encino, California
Investigative Site US222
Fountain Valley, California
Investigative Site US211
Los Angeles, California
Investigative Site US237
Los Angeles, California
Investigative Site US234
Northridge, California
Investigative Site US250
Santa Ana, California
Investigative Site US244
Castle Rock, Colorado
Investigative Site US252
Cromwell, Connecticut
Investigative Site US208
Boca Raton, Florida
Investigative Site US203
Hialeah, Florida
Investigative Site US258
Jacksonville, Florida
Investigative Site US206
Maitland, Florida
Investigative Site US223
Miami, Florida
Investigative Site US241
Miami, Florida
Investigative Site US202
Miami, Florida
Investigative Site US214
Tampa, Florida
Investigative Site US247
Tampa, Florida
Investigative Site US231
Columbus, Georgia
Investigative Site US225
Sandy Springs, Georgia
Investigative Site US207
Skokie, Illinois
Investigative Site US205
Plainfield, Indiana
Investigative Site US264
Lake Charles, Louisiana
Investigative Site US266
New Orleans, Louisiana
Investigative Site US254
Gambrills, Maryland
Investigative Site US201
Marriottsville, Maryland
Investigative Site US253
Milford, Massachusetts
Investigative Site US227
Needham, Massachusetts
Investigative Site US268
Worcester, Massachusetts
Investigative Site US238
Ann Arbor, Michigan
Investigative Site US230
Auburn Hills, Michigan
Investigative Site US251
St Louis, Missouri
Investigative Site US271
Wildwood, Missouri
Investigative Site US212
Missoula, Montana
Investigative Site US216
Las Vegas, Nevada
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.